Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study [0.03%]
Ixekizumab在银屑病关节炎中的留存率及影响治疗持久性的因素：一项意大利多中心研究的结果
Camilla Mazzanti,Marino Paroli,Gianluca Santoboni et al.
Camilla Mazzanti et al.
IXE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) in randomized controlled trials (RCTs). However, available dat...
Trends in Psoriatic Arthritis Management From 1993 to 2019: Rise of Biologics and Decline of Oral Small Molecules [0.03%]
银屑病关节炎的治疗趋势：生物制剂崛起，口服小分子药物式微（1993至2019年）
Brad R Woodie,Sarayu Balachandar,Alan B Fleischer Jr
Brad R Woodie
Background: Traditional oral small molecule disease-modifying antirheumatic drugs (OSMs) have historically been the cornerstone of psoriatic arthritis (PsA) management. However, biologics have gained prominence due to the...
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry [0.03%]
荷兰生物制剂登记处(BioCAPTURE)的女性银屑病患者药物生存率低，满意度差，不良事件多
Liana Barenbrug,Renate G van der Molen,Jake S F Maurits et al.
Liana Barenbrug et al.
Background: Drug survival of biologics for psoriasis has reported to be lower in females than males for first-generation biologics (TNF-α/interleukin (IL) 12/23 inhibitors (i)); insights for newer biologics (IL17i and IL...
Fatigue and the Impact of Musculoskeletal Pain on Quality of Life in Pediatric Patients With Psoriasis [0.03%]
银屑病患儿的疲劳和肌肉骨骼疼痛对生活质量的影响
Thaís Cugler Meneghetti,Vânia Oliveira Carvalho,Luciana Martins de Carvalho et al.
Thaís Cugler Meneghetti et al.
Background and aims: Musculoskeletal pain associated to psoriasis without the presence of psoriatic arthritis is a poor explored issue in pediatric population. The aim of this study was to compare the health-related quali...
Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion [0.03%]
慢性泛发性脓疱型银屑病的治疗：综述与专家意见
Boni Elewski,Mark G Lebwohl
Boni Elewski
Introduction: Generalized pustular psoriasis (GPP) is a rare, chronic inflammatory skin disease characterized by persistent symptoms and sudden flares of painful sterile pustules, sometimes accompanied by systemic inflammation. Patients wit...
Healthcare Resource Utilization Among Patients With Generalized Pustular Psoriasis: The Impact of Flares and Disease Severity [0.03%]
泛发性脓疱性银屑病患者的医疗资源利用情况：复发和疾病严重程度的影响
Megan H Noe,Layla Lavasani,Lawrence Rasouliyan et al.
Megan H Noe et al.
Background: Generalized pustular psoriasis (GPP) is a rare, chronic, often unpredictable, severe multisystemic autoinflammatory skin disease from which patients can experience flares, episodes of widespread eruptions of p...
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America [0.03%]
真实世界中选择银屑病系统治疗患者的指征——国际银屑病协会指南在北美的应用
Bruce Strober,Yichen Zhong,Adam Sima et al.
Bruce Strober et al.
Background: The International Psoriasis Council (IPC) updated the classification of psoriasis severity to guide clinical decision-making. According to IPC guidelines, patients are considered candidates for systemic therap...
The FORWARD Psoriasis Registry: Patient-Reported Outcomes in a Novel Psoriasis Registry and Comparison of Traditional, Dermatologist-Led Enrollment With Web-Based Patient Enrollment [0.03%]
FORWARD银屑病登记数据库：一项新型银屑病注册研究的患者报告结局及基于传统皮肤病学导向和基于网络患者的登记方法对比
William B Song,Kaleb Michaud,Sarah L Lonowski et al.
William B Song et al.
Background: Real-world evidence describing the natural history of all manifestations and severities of psoriasis is needed, as existing studies often recruit from a restricted patient population, and treatment failure and...
Tackling Multiple Biologic Failure in Psoriasis: Research and Advocacy Perspectives [0.03%]
应对银屑病生物制剂失败的挑战：研究与患者视角
Kathryn Haran,George Gondo,Payton Smith et al.
Kathryn Haran et al.
Psoriasis is an immune-mediated skin disease commonly treated with biologic therapies. While there are currently 12 different biologics approved for psoriasis, there still exists a challenging subset of patients who have tried and failed bi...